Current status of poly(ADP-ribose) polymerase inhibitors and future directions

References

• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymeraseNature2005434703591391715829966
   PubMed Web of Science ®Google Scholar
• FarmerHMcCabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• del RiveroJKohnECPARP Inhibitors: the cornerstone of DNA repair-targeted therapiesOncology (Williston Park)201731426527328412778
   PubMed Web of Science ®Google Scholar
• KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationJ Clin Oncol201533324425025366685
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med2012366151382139222452356
   PubMed Web of Science ®Google Scholar
• SwisherEMLinKKOzaAMRucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialLancet Oncol2017181758727908594
   PubMed Web of Science ®Google Scholar
• MirzaMRMonkBJHerrstedtJNiraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancerN Engl J Med2016375222154216427717299
   PubMed Web of Science ®Google Scholar
• LinKYKrausWLPARP inhibitors for cancer therapyCell2017169218328388401
   PubMedGoogle Scholar
• BoltonKLChenevix-TrenchGGohCAssociation between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancerJAMA2012307438239022274685
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMTimmsKMLiuSIncidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerClin Cancer Res20111751082108921233401
   PubMed Web of Science ®Google Scholar
• LordCJAshworthABRCAness revisitedNat Rev Cancer201616211012026775620
   PubMed Web of Science ®Google Scholar
• McCabeNTurnerNCLordCJDeficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibitionCancer Res200666168109811516912188
   PubMed Web of Science ®Google Scholar
• ChambonPWeillJDMandelPNicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzymeBiochem Biophys Res Commun196311394314019961
   PubMed Web of Science ®Google Scholar
• AshworthAA synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repairJ Clin Oncol200826223785379018591545
   PubMed Web of Science ®Google Scholar
• BrownJSO’CarriganBJacksonSPYapTATargeting DNA repair in cancer: beyond PARP inhibitorsCancer Discov20177203728003236
   PubMed Web of Science ®Google Scholar
• AméJCRolliVSchreiberVPARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymeraseJ Biol Chem199927425178601786810364231
   PubMed Web of Science ®Google Scholar
• McLornanDPListAMuftiGJApplying synthetic lethality for the selective targeting of cancerN Engl J Med20143711725173525354106
   PubMed Web of Science ®Google Scholar
• SchreiberVDantzerFAmeJCde MurciaGPoly (ADP-ribose): novel functions for an old moleculeNat Rev Mol Cell Biol20067751752816829982
   PubMed Web of Science ®Google Scholar
• LordCJAshworthAThe DNA damage response and cancer therapyNature201248128729422258607
   PubMed Web of Science ®Google Scholar
• PapaACarusoDStrudelMTomaoSTomaoFUpdate on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatmentJ Transl Med20161426727634150
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYDasBBTrapping of PARP1 and PARP2 by clinical PARP inhibitorsCancer Res201272215588559923118055
   PubMed Web of Science ®Google Scholar
• PlummerERCalvertHTargeting poly (ADP-ribose) polymerase: a two-armed strategy for cancer therapyClin Cancer Res200713216252625617975135
   PubMed Web of Science ®Google Scholar
• LordCJAshworthAPARP inhibitors: synthetic lethality in the clinicScience201735563301152115828302823
   PubMed Web of Science ®Google Scholar
• AnnunziataCMO’ShaughnessyJPoly (ADP-ribose) polymerase as a novel therapeutic target in cancerClin Cancer Res201016184517452620823142
   PubMedGoogle Scholar
• O’SullivanCCMoonDHKohnECLeeJMBeyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumorsFront Oncol201444224616882
   PubMedGoogle Scholar
• ShrivastavMDe HaroLPNickoloffJARegulation of DNA double-strand break repair pathway choiceCell Res200818113414718157161
   PubMed Web of Science ®Google Scholar
• BenafifSHallMAn update on PARP inhibitors for the treatment of cancerOnco Targets Ther2015851952825750544
   PubMed Web of Science ®Google Scholar
• ByersLAWangJNilssonMBProteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1Cancer Discov20122979881122961666
   PubMed Web of Science ®Google Scholar
• RatnamKLowJACurrent development of clinical inhibitors of poly (ADP-ribose) polymerase in oncologyClin Cancer Res20071351383138817332279
   PubMed Web of Science ®Google Scholar
• RouleauMPatelAHendzelMJKaufmannSHPoirierGGPARP inhibition: PARP1 and beyondNat Rev Cancer201010429330120200537
   PubMed Web of Science ®Google Scholar
• Hughes-DaviesLHuntsmanDRuasMEMSY links the BRCA2 pathway to sporadic breast and ovarian cancerCell2003115552353514651845
   PubMedGoogle Scholar
• LimDNgeowJEvaluation of the methods to identify patients who may benefit from PARP inhibitor useEndocr Relat Cancer2016236R267R28527226207
   PubMedGoogle Scholar
• PenningtonKPWalshTHarrellMIGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasClin Cancer Res201420376477524240112
   PubMed Web of Science ®Google Scholar
• MateoJCarreiraSSandhuSDNA-repair defects and olaparib in metastatic prostate cancerN Engl J Med20153731697170826510020
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinomaNature2011474735360961521720365
   PubMed Web of Science ®Google Scholar
• PommierYO’ConnorMJde BonoJLaying a trap to kill cancer cells: PARP inhibitors and their mechanisms of actionSci Transl Med20168362s17
   Google Scholar
• Postel-VinaySVanheckeEOlaussenKALordCJAshworthASoriaJCThe potential of exploiting DNA-repair defects for optimizing lung cancer treatmentNat Rev Clin Oncol20129314415522330686
   PubMedGoogle Scholar
• MatulonisUAMonkBJPARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?Ann Oncol20172844344728057663
   PubMed Web of Science ®Google Scholar
• MuraiJZhangYMorrisJRationale for poly (ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibitionJ Pharmacol Exp Ther2014349340841624650937
   PubMed Web of Science ®Google Scholar
• IhnenMzu EulenburgCKolarovaTTherapeutic potential of the poly (ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancerMol Cancer Ther20131261002101523729402
   PubMed Web of Science ®Google Scholar
• DréanALordCJAshworthAPARP inhibitor combination therapyCrit Rev Oncol Hematol2016108738527931843
   PubMed Web of Science ®Google Scholar
• LuYKwintkiewiczJLiuYChemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repairCancer Res20177771709171828202508
   PubMed Web of Science ®Google Scholar
• TateishiKHiguchiFMillerJJThe alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD+ depletion-mediated cytotoxicityCancer Res201777154102411528625978
   PubMedGoogle Scholar
• FongPCBossDSYapTAInhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med2009361212313419553641
   PubMed Web of Science ®Google Scholar
• FongPCYapTABossDSPoly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol201028152512251920406929
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialLancet Oncol20141585286124882434
   PubMed Web of Science ®Google Scholar
• TuttARobsonMGarberJEOral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet2010376973723524420609467
   PubMed Web of Science ®Google Scholar
• HopkinsTAShiYRodriguezLEMechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitorsMol Cancer Res201513111465147726217019
   PubMed Web of Science ®Google Scholar
• de BonoJRamanathanRKMinaLPhase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancersCancer Discov20177662062928242752
   PubMed Web of Science ®Google Scholar
• KristeleitRSBurrisHALoRussoPPhase 1/2 study of oral rucaparib: final phase 1 resultsJ Clin Oncol201432suppl abstr2573
   Google Scholar
• Shapira-FrommerROzaAMDomchekSMA phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutationJ Clin Oncol201533suppl abstr5513
   PubMedGoogle Scholar
• PuhallaSBeumerJHPahujaSFinal results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt)J Clin Oncol201432suppl abstr2570
   PubMedGoogle Scholar
• ColemanRLSillMWBell-McGuinnKA phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation – an NRG Oncology/Gynecologic Oncology Group studyGynecol Oncol2015137338639125818403
   PubMed Web of Science ®Google Scholar
• SandhuSKSchelmanWRWildingGThe poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialLancet Oncol201314988289223810788
   PubMed Web of Science ®Google Scholar
• Bell-McGuinnKMKonnerJATewWPA phase 2, single arm study of iniparib in patients with BRCA1 or BRCA2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancerInt J Gynecol Cancer201626225526026745694
   PubMed Web of Science ®Google Scholar
• WagnerLMProfile of veliparib and its potential in the treatment of solid tumorsOnco Targets Ther201581931193926251615
   PubMed Web of Science ®Google Scholar
• OzaAMCibulaDBenzaquenAOOlaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialLancet Oncol201516879725481791
   PubMed Web of Science ®Google Scholar
• BangYJImSALeeKWRandomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancerJ Clin Oncol2015333858386526282658
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJOsborneCPippenJEIniparib plus chemotherapy in metastatic triple-negative breast cancerN Engl J Med2011364320521421208101
   PubMed Web of Science ®Google Scholar
• LichtSCaoHLiZMechanism of action of iniparib: stimulation of reactive oxygen species (ROS) production in an iniparib-sensitive breast cancer cell lineMol Cancer Ther201110supl 11 abstrA226
   Google Scholar
• GuhaMPARP inhibitors stumble in breast cancerNat Biotechnol20112937337421552220
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJSchwartzbergLDansoMAPhase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancerJ Clin Oncol201432343840384725349301
   PubMed Web of Science ®Google Scholar
• ChanNBristowRG“Contextual” synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repairClin Cancer Res2010164553456020823145
   PubMed Web of Science ®Google Scholar
• LiuJFBarryWTBirrerMCombination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 studyLancet Oncol201415111207121425218906
   PubMed Web of Science ®Google Scholar
• O’Sullivan CoyneGChenAPMeehanRDoroshowJHPARP inhibitors in reproductive system cancers: current use and developmentsDrugs201777211313028078645
   PubMed Web of Science ®Google Scholar
• LYNPARZA™ (olaparib) capsules, for oral use [prescribing information approved by the US FDA] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdfAccessed August 22, 2017
   Google Scholar
• StoverEHKonstantinopoulosPAMatulonisUASwisherEMBiomarkers of response and resistance to DNA repair targeted therapiesClin Cancer Res201622235651566027678458
   PubMed Web of Science ®Google Scholar
• RUBRACA™ (rucaparib) tablets, for oral use [prescribing information approved by the US FDA] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdfAccessed August 22, 2017
   Google Scholar
• ZEJULATM (niraparib) capsules, for oral use [prescribing information approved by the US FDA] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdfAccessed August 22, 2017
   Google Scholar
• WiggansAJCassGKBryantAPoly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerCochrane Database Syst Rev20155CD007929
   Google Scholar
• SakaiWSwisherEMKarlanBYSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature200845171821116112018264087
   PubMed Web of Science ®Google Scholar
• YachidaSJonesSBozicIDistant metastasis occurs late during the genetic evolution of pancreatic cancerNature201046773191114111720981102
   PubMed Web of Science ®Google Scholar
• TelliMLTimmsKMReidJHomologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancerClin Cancer Res201622153764377326957554
   PubMed Web of Science ®Google Scholar
• GraeserMMcCarthyALordCJA marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancerClin Cancer Res201016246159616820802015
   PubMed Web of Science ®Google Scholar
• von MinckwitzGMüllerBMLoiblSCytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapyJ Clin Oncol201129162150215721519019
   PubMedGoogle Scholar
• BrennerJCFengFYHanSPARP-1 inhibition as a targeted strategy to treat Ewing’s sarcomaCancer Res20127271608161322287547
   PubMed Web of Science ®Google Scholar
• MichelsJVitaleIGalluzziLCisplatin resistance associated with PARP hyperactivationCancer Res20137372271228023554447
   PubMed Web of Science ®Google Scholar
• MontoniARobuMPouliotEShahGMResistance to PARP-inhibitors in cancer therapyFront Pharmacol201341823450678
   PubMed Web of Science ®Google Scholar
• EdwardsSLBroughRLordCJResistance to therapy caused by intragenic deletion in BRCA2Nature200845171821111111518264088
   PubMed Web of Science ®Google Scholar
• BarberLJSandhuSChenLSecondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitorJ Pathol2013229342242923165508
   PubMed Web of Science ®Google Scholar
• SwisherEMSakaiWKarlanBYWurzKUrbanNTaniguchiTSecondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistanceCancer Res20086882581258618413725
   PubMed Web of Science ®Google Scholar
• NorquistBWurzKAPennilCCSecondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomasJ Clin Oncol201129223008301521709188
   PubMed Web of Science ®Google Scholar
• DhillonKKSwisherEMTaniguchiTSecondary mutations of BRCA1/2 and drug resistanceCancer Sci201110266366921205087
   PubMed Web of Science ®Google Scholar
• BuntingSFCallénEWongN53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaksCell2010141224325420362325
   PubMed Web of Science ®Google Scholar
• BouwmanPAlyAEscandellJM53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersNat Struct Mol Biol201017668869520453858
   PubMed Web of Science ®Google Scholar
• SourisseauTManiotisDMcCarthyAAurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibitionEMBO Mol Med20102413014220373286
   PubMed Web of Science ®Google Scholar
• Mendes-PereiraAMMartinSABroughRSynthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Mol Med200916–731532220049735
   PubMed Web of Science ®Google Scholar
• LiuXHanEKAndersonMAcquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathwaysMol Cancer Res20097101686169219825992
   PubMed Web of Science ®Google Scholar
• KondrashovaONguyenMShield-ArtinKSecondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinomaCancer Discov20177998499828588062
   PubMed Web of Science ®Google Scholar
• RottenbergSJaspersJEKersbergenAHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProc Natl Acad Sci U S A200810544170791708418971340
   PubMed Web of Science ®Google Scholar
• KimYKimASharipAReverse the resistance to PARP inhibitorsInt J Biol Sci20171319820828255272
   PubMed Web of Science ®Google Scholar
• Ter BruggePKristelPvan der BurgEMechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancerJ Natl Cancer Inst201610811djw148
   Google Scholar
• ChoiYEMeghaniKBraultMEPlatinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancerCell Rep201614342943926774475
   PubMed Web of Science ®Google Scholar
• DuYYamaguchiHWeiYBlocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitorsNat Med20162219420126779812
   PubMed Web of Science ®Google Scholar
• EspositoMTZhaoLFungTKSynthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitorsNat Med201521121481149026594843
   PubMed Web of Science ®Google Scholar
• PatchAMChristieELEtemadmoghadamDWhole-genome characterization of chemoresistant ovarian cancerNature2015521755348949426017449
   PubMed Web of Science ®Google Scholar
• BoothCMEisenhauerEAProgression-free survival: meaningful or simply measurable?J Clin Oncol201230101030103322370321
   PubMed Web of Science ®Google Scholar
• SonnenblickAde AzambujaEAzimHAJrPiccartMAn update on PARP inhibitors – moving to the adjuvant settingNat Rev Clin Oncol2015121274125286972
   PubMed Web of Science ®Google Scholar